Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
31.31
-0.99 (-3.07%)
At close: Dec 12, 2025, 4:00 PM EST
31.19
-0.12 (-0.38%)
After-hours: Dec 12, 2025, 7:44 PM EST
Genmab Revenue
Genmab had revenue of $1.02B in the quarter ending September 30, 2025, with 25.25% growth. This brings the company's revenue in the last twelve months to $3.47B, up 18.01% year-over-year. In the year 2024, Genmab had annual revenue of $3.00B with 23.13% growth.
Revenue (ttm)
$3.47B
Revenue Growth
+18.01%
P/S Ratio
5.07
Revenue / Employee
$1,433,881
Employees
2,682
Market Cap
19.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.00B | 564.17M | 23.13% |
| Dec 31, 2023 | 2.44B | 351.45M | 16.83% |
| Dec 31, 2022 | 2.09B | 800.56M | 62.19% |
| Dec 31, 2021 | 1.29B | -372.56M | -22.45% |
| Dec 31, 2020 | 1.66B | 854.43M | 106.10% |
| Dec 31, 2019 | 805.32M | 340.75M | 73.35% |
| Dec 31, 2018 | 464.57M | 83.37M | 21.87% |
| Dec 31, 2017 | 381.20M | -144.81M | -27.53% |
| Dec 31, 2016 | 526.01M | 195.32M | 59.07% |
| Dec 31, 2015 | 330.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GMAB News
- 3 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire
- 3 days ago - Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript - Seeking Alpha
- 4 days ago - Genmab to Hold 2025 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 6 days ago - Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - Business Wire
- 7 days ago - Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma - Business Wire
- 8 days ago - Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) - Business Wire
- 10 days ago - Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes - GlobeNewsWire